DB:MRK

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

MERCK Kommanditgesellschaft auf Aktien

Executive Summary

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. More Details


Snowflake Analysis

Solid track record average dividend payer.


Similar Companies

Share Price & News

How has MERCK Kommanditgesellschaft auf Aktien's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MRK has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

4.4%

MRK

1.0%

DE Pharmaceuticals

-5.2%

DE Market


1 Year Return

22.4%

MRK

-1.1%

DE Pharmaceuticals

-3.8%

DE Market

Return vs Industry: MRK exceeded the German Pharmaceuticals industry which returned -0.8% over the past year.

Return vs Market: MRK exceeded the German Market which returned 0.2% over the past year.


Shareholder returns

MRKIndustryMarket
7 Day4.4%1.0%-5.2%
30 Day5.7%-6.6%-2.2%
90 Day16.0%-6.5%-4.2%
1 Year24.0%22.4%2.0%-1.1%-0.8%-3.8%
3 Year47.1%41.3%22.9%8.8%-3.7%-12.1%
5 Year54.4%44.7%22.9%1.8%16.7%0.1%

Price Volatility Vs. Market

How volatile is MERCK Kommanditgesellschaft auf Aktien's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MERCK Kommanditgesellschaft auf Aktien undervalued compared to its fair value and its price relative to the market?

10.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MRK (€130.1) is trading below our estimate of fair value (€145.4)

Significantly Below Fair Value: MRK is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: MRK is poor value based on its PE Ratio (40.1x) compared to the XE Pharmaceuticals industry average (22.3x).

PE vs Market: MRK is poor value based on its PE Ratio (40.1x) compared to the German market (22.3x).


Price to Earnings Growth Ratio

PEG Ratio: MRK is poor value based on its PEG Ratio (2.8x)


Price to Book Ratio

PB vs Industry: MRK is good value based on its PB Ratio (3.2x) compared to the DE Pharmaceuticals industry average (6.2x).


Next Steps

Future Growth

How is MERCK Kommanditgesellschaft auf Aktien forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?

14.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MRK's forecast earnings growth (14.3% per year) is above the savings rate (0.2%).

Earnings vs Market: MRK's earnings (14.3% per year) are forecast to grow slower than the German market (26.2% per year).

High Growth Earnings: MRK's earnings are forecast to grow, but not significantly.

Revenue vs Market: MRK's revenue (5.9% per year) is forecast to grow slower than the German market (6% per year).

High Growth Revenue: MRK's revenue (5.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MRK's Return on Equity is forecast to be low in 3 years time (12.9%).


Next Steps

Past Performance

How has MERCK Kommanditgesellschaft auf Aktien performed over the past 5 years?

0.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MRK has high quality earnings.

Growing Profit Margin: MRK's current net profit margins (8.4%) are higher than last year (7.3%).


Past Earnings Growth Analysis

Earnings Trend: MRK's earnings have grown by 0.4% per year over the past 5 years.

Accelerating Growth: MRK's earnings growth over the past year (26.9%) exceeds its 5-year average (0.4% per year).

Earnings vs Industry: MRK earnings growth over the past year (26.9%) exceeded the Pharmaceuticals industry 13.1%.


Return on Equity

High ROE: MRK's Return on Equity (7.9%) is considered low.


Next Steps

Financial Health

How is MERCK Kommanditgesellschaft auf Aktien's financial position?


Financial Position Analysis

Short Term Liabilities: MRK's short term assets (€9.7B) do not cover its short term liabilities (€10.1B).

Long Term Liabilities: MRK's short term assets (€9.7B) do not cover its long term liabilities (€15.7B).


Debt to Equity History and Analysis

Debt Level: MRK's debt to equity ratio (75.3%) is considered high.

Reducing Debt: MRK's debt to equity ratio has increased from 58.7% to 75.3% over the past 5 years.

Debt Coverage: MRK's debt is not well covered by operating cash flow (19.5%).

Interest Coverage: MRK's interest payments on its debt are well covered by EBIT (7.3x coverage).


Balance Sheet


Next Steps

Dividend

What is MERCK Kommanditgesellschaft auf Aktien current dividend yield, its reliability and sustainability?

0.99%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: MRK's dividend (0.99%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.25%).

High Dividend: MRK's dividend (0.99%) is low compared to the top 25% of dividend payers in the German market (3.77%).


Stability and Growth of Payments

Stable Dividend: MRK's dividends per share have been stable in the past 10 years.

Growing Dividend: MRK's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (39.9%), MRK's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: MRK's dividends in 3 years are forecast to be well covered by earnings (19.5% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average management tenure


CEO

Stefan Oschmann (63 yo)

4.5yrs

Tenure

€9,823,000

Compensation

Dr. Stefan Oschmann has been the Chairman of Executive Board and Chief Executive Officer of Merck KGaA since April 30, 2016. Dr. Oschmann has been a Member of Executive Board for Merck KGaA since January 1 ...


CEO Compensation Analysis

Compensation vs Market: Stefan's total compensation ($USD11.61M) is above average for companies of similar size in the German market ($USD5.27M).

Compensation vs Earnings: Stefan's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Stefan Oschmann
Chairman of Executive Board & CEO4.5yrs€9.82mno data
Belen Garijo Lopez
Vice Chairman of the Executive Board0.25yr€5.80mno data
Marcus Kuhnert
CFO & Member of Executive Board6.42yrs€4.56mno data
Kai Beckmann
CEO of Performance Materials & Member of the Executive Board9.5yrs€4.95mno data
Gerhard Schmitz
Head of Global Accounting6.92yrsno datano data
Dirk Toepfer
Chief Information Officer2.58yrsno datano data
Constantin Fest
Head of Investor Relations7.75yrsno datano data
Friederike Rotsch
Group General Counsel and Head of Group Legal & Compliance6.5yrsno datano data
Barbara Weiland
Chief Compliance Officer1.25yrsno datano data
Constantin Birnstiel
Head of Group Communications3.42yrsno datano data
Dietmar Eidens
Head of the Global HR Business Partner Organization5.75yrsno datano data
Michael Wilk
Head of Polyproduction - Darmstadtno datano datano data

5.8yrs

Average Tenure

55yo

Average Age

Experienced Management: MRK's management team is seasoned and experienced (5.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Edeltraud Glänzer
Independent Member of Supervisory Board12.58yrs€50.00kno data
Zoe Tang
Non-Executive Director3.83yrsno datano data
Wolfgang Büchele
Independent Chairman of Supervisory Board6.42yrs€97.75kno data
Jürgen Glaser
Independent Member of Supervisory Board1.5yrs€35.19kno data
Helga Rübsamen-Schaeff
Independent Member of Supervisory Board6.42yrs€50.00kno data
Gabriele Eismann
Independent Member of Supervisory Board6.42yrs€50.75kno data
Dietmar Oeter
Independent Member of Supervisory Board6.42yrs€50.75kno data
Alexander Putz
Member of Supervisory Board0.42yr€15.69kno data
Sascha Held
Independent Vice Chairman of Supervisory Board0.17yr€35.19kno data
Michael Kleinemeier
Independent Member of Supervisory Board1.5yrs€34.44kno data
Renate Koehler
Independent Member of Supervisory Board1.5yrs€35.19kno data
Anne Lange
Independent Member of Supervisory Board1.5yrs€34.44kno data

2.7yrs

Average Tenure

58yo

Average Age

Experienced Board: MRK's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

MERCK Kommanditgesellschaft auf Aktien's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MERCK Kommanditgesellschaft auf Aktien
  • Ticker: MRK
  • Exchange: DB
  • Founded: 1668
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €57.325b
  • Shares outstanding: 434.78m
  • Website: https://www.merckgroup.com

Number of Employees


Location

  • MERCK Kommanditgesellschaft auf Aktien
  • Frankfurter Strasse 250
  • Darmstadt
  • Hessen
  • 64293
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MKGA.FOTCPK (Pink Sheets LLC)YesBearer SharesUSUSDOct 1995
MRKDB (Deutsche Boerse AG)YesBearer SharesDEEUROct 1995
MRKXTRA (XETRA Trading Platform)YesBearer SharesDEEUROct 1995
0O14LSE (London Stock Exchange)YesBearer SharesGBEUROct 1995
MRKDBATS-CHIXE (BATS 'Chi-X Europe')YesBearer SharesGBEUROct 1995
MRCKWBAG (Wiener Boerse AG)YesBearer SharesATEUROct 1995
MERSWX (SIX Swiss Exchange)YesBearer SharesCHCHFOct 1995
MRKBIT (Borsa Italiana)YesBearer SharesITEUROct 1995
MKKG.YOTCPK (Pink Sheets LLC)SPONSORED ADRUSUSDSep 2007
MRKCBST (Boerse-Stuttgart)SPONSORED ADRDEEURSep 2007

Biography

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer or multiple sclerosis, inferti ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 22:02
End of Day Share Price2020/10/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.